Eli Lilly and Company has announced a significant debt offering, issuing multiple series of notes amounting to a total of approximately $6.71 billion in net proceeds. The offering includes $750 million in Floating Rate Notes due 2028, $1 billion in 4.000% Notes due 2028, $750 million in 4.250% Notes due 2031, $1 billion in 4.550% Notes due 2032, $1.25 billion in 4.900% Notes due 2035, $1 billion in 5.550% Notes due 2055, and $1 billion in 5.650% Notes due 2065. The maturity dates for these notes range from October 15, 2028, to October 15, 2065, with interest rates varying from 4.000% to 5.650% per annum, payable semi-annually. The offering was registered under a Registration Statement on Form S-3.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.